Abstract
Andrew Farlow reflects on new research by David Boulware and colleagues, highlighting current challenges in treating cryptoccocal meningitis and the relative neglect of investment in research to treat this disease.
MeSH terms
-
Cost-Benefit Analysis / methods*
-
Humans
-
Meningitis, Cryptococcal / drug therapy*
-
Meningitis, Cryptococcal / economics*
Grants and funding
The author received no specific funding to write this paper.